NewAmsterdam Pharma Total Asset vs. Beta
| NAMSW Stock | 9.53 0.62 6.11% |
NewAmsterdam Pharma Total Assets |
|
For NewAmsterdam Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NewAmsterdam Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NewAmsterdam Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NewAmsterdam Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NewAmsterdam Pharma over time as well as its relative position and ranking within its peers.
NewAmsterdam |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NewAmsterdam Pharma. If investors know NewAmsterdam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NewAmsterdam Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 0.373 | Quarterly Revenue Growth 8.898 | Return On Assets (0.29) | Return On Equity (0.47) |
The market value of NewAmsterdam Pharma is measured differently than its book value, which is the value of NewAmsterdam that is recorded on the company's balance sheet. Investors also form their own opinion of NewAmsterdam Pharma's value that differs from its market value or its book value, called intrinsic value, which is NewAmsterdam Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NewAmsterdam Pharma's market value can be influenced by many factors that don't directly affect NewAmsterdam Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NewAmsterdam Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if NewAmsterdam Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NewAmsterdam Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
NewAmsterdam Pharma Beta vs. Total Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining NewAmsterdam Pharma's current stock value. Our valuation model uses many indicators to compare NewAmsterdam Pharma value to that of its competitors to determine the firm's financial worth. NewAmsterdam Pharma is regarded fourth in total asset category among its peers. It also is regarded fourth in beta category among its peers . At this time, NewAmsterdam Pharma's Total Assets are fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value NewAmsterdam Pharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.NewAmsterdam Beta vs. Total Asset
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
NewAmsterdam Pharma |
| = | 347.1 M |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
NewAmsterdam Pharma |
| = | -0.001 |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
NewAmsterdam Beta Comparison
NewAmsterdam Pharma is currently under evaluation in beta category among its peers.
Beta Analysis
As returns on the market increase, returns on owning NewAmsterdam Pharma are expected to decrease at a much lower rate. During the bear market, NewAmsterdam Pharma is likely to outperform the market.
NewAmsterdam Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in NewAmsterdam Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NewAmsterdam Pharma will eventually generate negative long term returns. The profitability progress is the general direction of NewAmsterdam Pharma's change in net profit over the period of time. It can combine multiple indicators of NewAmsterdam Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 4.4 M | 3.6 M | |
| Net Interest Income | 3.4 M | 3.6 M | |
| Interest Income | 11.3 M | 11.8 M | |
| Operating Income | -165.7 M | -157.4 M | |
| Net Loss | -176.9 M | -168.1 M | |
| Income Before Tax | -160.2 M | -152.2 M | |
| Total Other Income Expense Net | 5.5 M | 5.8 M | |
| Net Loss | -160.3 M | -152.3 M | |
| Income Tax Expense | 27 K | 25.6 K | |
| Net Loss | (2.15) | (2.26) | |
| Income Quality | 0.88 | 0.74 | |
| Net Income Per E B T | 0.99 | 0.88 |
NewAmsterdam Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on NewAmsterdam Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NewAmsterdam Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NewAmsterdam Pharma's important profitability drivers and their relationship over time.
Use NewAmsterdam Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NewAmsterdam Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NewAmsterdam Pharma will appreciate offsetting losses from the drop in the long position's value.NewAmsterdam Pharma Pair Trading
NewAmsterdam Pharma Pair Trading Analysis
The ability to find closely correlated positions to NewAmsterdam Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NewAmsterdam Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NewAmsterdam Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NewAmsterdam Pharma to buy it.
The correlation of NewAmsterdam Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NewAmsterdam Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NewAmsterdam Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NewAmsterdam Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your NewAmsterdam Pharma position
In addition to having NewAmsterdam Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Insurance Thematic Idea Now
Insurance
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Insurance theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Insurance Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.